TY - JOUR
T1 - NAA10 p.(N101K) disrupts N-terminal acetyltransferase complex NatA and is associated with developmental delay and hemihypertrophy
AU - CAUSES Study
AU - McTiernan, Nina
AU - Gill, Harinder
AU - Prada, Carlos E.
AU - Pachajoa, Harry
AU - Lores, Juliana
AU - Arnesen, Thomas
AU - Adam, Shelin
AU - Du Souich, Christele
AU - Elliott, Alison
AU - Lehman, Anna
AU - Mwenifumbo, Jill
AU - Nelson, Tanya
AU - Van Karnebeek, Clara
AU - Friedman, Jan
N1 - Funding Information: Funding The work has been supported by Mining for Miracles, British Columbia Children’s Hospital Foundation and Genome British Columbia, the Research Council of Norway (project 249843), the Norwegian Health Authorities of Western Norway (project 912176), and the Norwegian Cancer Society. The funding bodies had no role in the design of the study, collection, analysis, or interpretation of data or in writing the manuscript. Publisher Copyright: © 2020, The Author(s).
PY - 2021/2
Y1 - 2021/2
N2 - Nearly half of all human proteins are acetylated at their N-termini by the NatA N-terminal acetyltransferase complex. NAA10 is evolutionarily conserved as the catalytic subunit of NatA in complex with NAA15, but may also have NatA-independent functions. Several NAA10 variants are associated with genetic disorders. The phenotypic spectrum includes developmental delay, intellectual disability, and cardiac abnormalities. Here, we have identified the previously undescribed NAA10 c.303C>A and c.303C>G p.(N101K) variants in two unrelated girls. These girls have developmental delay, but they both also display hemihypertrophy a feature normally not observed or registered among these cases. Functional studies revealed that NAA10 p.(N101K) is completely impaired in its ability to bind NAA15 and to form an enzymatically active NatA complex. In contrast, the integrity of NAA10 p.(N101K) as a monomeric acetyltransferase is intact. Thus, this NAA10 variant may represent the best example of the impact of NatA mediated N-terminal acetylation, isolated from other potential NAA10-mediated cellular functions and may provide important insights into the phenotypes observed in individuals expressing pathogenic NAA10 variants.
AB - Nearly half of all human proteins are acetylated at their N-termini by the NatA N-terminal acetyltransferase complex. NAA10 is evolutionarily conserved as the catalytic subunit of NatA in complex with NAA15, but may also have NatA-independent functions. Several NAA10 variants are associated with genetic disorders. The phenotypic spectrum includes developmental delay, intellectual disability, and cardiac abnormalities. Here, we have identified the previously undescribed NAA10 c.303C>A and c.303C>G p.(N101K) variants in two unrelated girls. These girls have developmental delay, but they both also display hemihypertrophy a feature normally not observed or registered among these cases. Functional studies revealed that NAA10 p.(N101K) is completely impaired in its ability to bind NAA15 and to form an enzymatically active NatA complex. In contrast, the integrity of NAA10 p.(N101K) as a monomeric acetyltransferase is intact. Thus, this NAA10 variant may represent the best example of the impact of NatA mediated N-terminal acetylation, isolated from other potential NAA10-mediated cellular functions and may provide important insights into the phenotypes observed in individuals expressing pathogenic NAA10 variants.
UR - http://www.scopus.com/inward/record.url?scp=85091426266&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41431-020-00728-2
DO - https://doi.org/10.1038/s41431-020-00728-2
M3 - Article
C2 - 32973342
SN - 1018-4813
VL - 29
SP - 280
EP - 288
JO - European journal of human genetics
JF - European journal of human genetics
IS - 2
ER -